Stay updated with breaking news from Nature Structural. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.
A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.
A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.
A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.
A team of infectious disease advisers will soon look at the results of Merck's clinical trial and decide whether to recommend emergency use authorization for the first pill to treat early-stage COVID-19.